N@N

Derma Sciences to Present at the Rodman & Renshaw 12th Annual Global Investment Conference

^{Published on 2010-09-07 09:41:04 - Market Wire}
 

PRINCETON, N.J.--([ BUSINESS WIRE ])--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that the company will be participating in the Rodman & Renshaw 12th Annual Global Investment Conference being held at the Palace Hotel in New York City from September 13th a" 15th, 2010. Edward J. Quilty, Chairman and CEO, will deliver the Companya™s corporate presentation on Tuesday, September 14th, at 11:15 a.m. (Eastern Time).

The presentation will be webcast live at [ http://www.wsw.com/webcast/rrshq18/dsci ] and on the Investor Relations section of the Companya™s website at [ www.dermasciences.com ], where it will also be archived for 90 days.

Mr. Quilty will be available for one-on-one meetings with investors participating in the Rodman & Renshaw Global Investment Conference. For those who would like to schedule an appointment with Derma Sciences management, please contact Kim Golodetz, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at [ kgolodetz@lhai.com ] or contact your Rodman & Renshaw representative.

About Derma Sciences, Inc.

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace, traditional dressings, advanced wound care dressings and pharmaceutical wound care products. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 leg ulcer patients. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudates, and BIOGUARD® for infection prevention. Derma Sciences expects to complete the efficacy portion of its Phase II clinical study with DSC127, a novel pharmaceutical for accelerated wound healing and scar reduction, by the end of 2010.

For more information please visit [ www.dermasciences.com ].

Forward-Looking Statements

Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's fillings with the U.S. Securities and Exchange Commission.